Zepbound & GLP-1 Medications for Obstructive Sleep Apnea
Zepbound (tirzepatide) is the first FDA-approved medication for treating obstructive sleep apnea in adults with obesity. In landmark clinical trials, it reduced sleep apnea severity by 50-59% and helped nearly half of participants reach mild or remission-level disease. Here's what you need to know about this new treatment option and how it fits into comprehensive sleep apnea care.
What Is Zepbound?
Zepbound (tirzepatide) is a once-weekly injectable medication that became the first drug FDA-approved specifically for treating moderate to severe obstructive sleep apnea (OSA) in adults with obesity. It is used in combination with a reduced-calorie diet and increased physical activity.
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist — meaning it activates two hormone pathways involved in appetite regulation and metabolism. While it is often grouped with "GLP-1 medications," it is technically a dual agonist that works through both GIP and GLP-1 receptors.
- First medication FDA-approved specifically for OSA
- Once-weekly subcutaneous injection
- Dual GIP/GLP-1 receptor agonist (not a pure GLP-1 drug)
- Approved for moderate to severe OSA in adults with obesity
Based on the SURMOUNT-OSA trials (469 participants, 52 weeks) and a retrospective study of 42,300 patients.
What the Clinical Trials Show
SURMOUNT-OSA: The Landmark Trials
The FDA approval was based on two phase 3 randomized controlled trials published in the New England Journal of Medicine, enrolling 469 adults with moderate-to-severe OSA (AHI of 15 or more events per hour) and obesity (BMI of 30 or above) across 60 sites in nine countries. Participants received tirzepatide or placebo for 52 weeks. In patients not using PAP therapy, tirzepatide reduced AHI by 25.3 events per hour versus 5.3 with placebo. In patients continuing PAP therapy, the reduction was 29.3 versus 5.5 events per hour.
Benefits Beyond Sleep Apnea
Beyond reducing sleep apnea severity, trial participants experienced significant improvements in other health markers. Body weight decreased by 17.7-19.6% with tirzepatide versus 1.6-2.3% with placebo. Patients also saw meaningful reductions in systolic blood pressure, hypoxic burden (the amount of oxygen deprivation during sleep), and high-sensitivity C-reactive protein, a marker of inflammation linked to cardiovascular risk.
Side Effects
The most common adverse events were gastrointestinal — including diarrhea, nausea, and vomiting — typically mild to moderate in severity and occurring primarily during the dose escalation period. These side effects are consistent with the known profile of GLP-1-based medications and generally improve as the body adjusts to the medication.
How Tirzepatide Compares to Other Treatments
Network meta-analyses comparing different medication-based approaches have consistently demonstrated tirzepatide's advantages for OSA treatment. Tirzepatide produced the greatest reduction in AHI (approximately 21.9 events per hour) compared to GLP-1 receptor agonists alone (approximately 5.2 events per hour) and SGLT-2 inhibitors (approximately 7.7 events per hour), along with the most substantial decreases in body weight and blood pressure.
Among other GLP-1 receptor agonists, liraglutide has demonstrated some efficacy in reducing sleep-disordered breathing events, though the effect appears smaller than that observed with tirzepatide. A large comparative study of patients with obesity, type 2 diabetes, and OSA found that tirzepatide demonstrated superior reductions in mortality risk compared to both SGLT-2 inhibitors and GLP-1 receptor agonists.
It is important to note that other commonly known medications in this class have different FDA-approved indications. Ozempic (semaglutide) is approved for type 2 diabetes management and cardiovascular risk reduction, but not for OSA. Mounjaro contains the same active ingredient as Zepbound (tirzepatide), but is approved only for type 2 diabetes — not for sleep apnea or weight management.
Current clinical guidance recommends that anti-obesity medications and bariatric surgery are more effective than lifestyle interventions alone for achieving weight loss in OSA patients. Most patients achieve 15-20% weight loss in one year with optimal use of incretin-based medications. A comprehensive review of pharmacotherapy for OSA concluded that weight-loss agents, particularly tirzepatide, represent the most promising medication-based treatment option available.
What You Should Know Before Starting Treatment
Start With a Diagnosis
Zepbound is approved specifically for moderate to severe OSA in adults with obesity. Before considering this treatment, you need an accurate diagnosis of your sleep apnea severity through a sleep study. An ENT evaluation can also identify whether anatomic factors like nasal obstruction or enlarged tonsils are contributing to your condition.
At-Home Sleep Testing AvailableDon't Stop CPAP on Your Own
The clinical trials did not evaluate when or how to discontinue PAP therapy. While many participants achieved significantly milder sleep apnea, any changes to your CPAP use should be guided by your sleep medicine provider and confirmed with follow-up sleep testing. Improvement can begin as early as 4 weeks, but statistically significant results were not seen until about 20 weeks.
CPAP ManagementPrescribed In-Clinic
Capital ENT prescribes Zepbound directly — no referral needed. We can also evaluate whether anatomic issues like a deviated septum, enlarged turbinates, or tongue base obstruction are contributing to your OSA. For many patients, combining Zepbound with a targeted surgical or CPAP approach produces the best outcomes.
No Referral RequiredReal-World Evidence & Long-Term Outlook
Emerging real-world data reinforces the clinical trial findings. A large retrospective study of 42,300 patients with OSA and obesity found that tirzepatide was associated with a 56% reduction in all-cause mortality, along with significant reductions in major cardiovascular events and major kidney events compared to lifestyle interventions alone. These benefits were consistent across most patient groups regardless of age, sex, BMI, or CPAP use.
Research into the time course of improvement shows that measurable reductions in sleep apnea begin as early as week 4 of treatment, though the treatment difference compared to placebo does not become statistically significant until approximately week 20. The magnitude of AHI improvement correlates with weight loss, and studies suggest that treating both sleep-disordered breathing and obesity together is important for optimizing heart and metabolic health benefits.
- Real-world mortality reduction of 56% compared to lifestyle changes alone
- Benefits consistent regardless of age, sex, BMI, or CPAP use
- Improvements in cardiovascular and kidney outcomes
- AHI reductions begin as early as week 4 of treatment
Data from a retrospective cohort study comparing tirzepatide to lifestyle interventions alone in patients with OSA and obesity.
GLP-1 Medications & Sleep Apnea FAQ
Yes. Zepbound (tirzepatide) became the first medication FDA-approved specifically for treating moderate to severe obstructive sleep apnea in adults with obesity. The approval was based on the SURMOUNT-OSA clinical trials, two phase 3 randomized controlled trials published in the New England Journal of Medicine that demonstrated significant reductions in sleep apnea severity over 52 weeks. The medication is used in combination with a reduced-calorie diet and increased physical activity.
The clinical trials did not evaluate the timing or appropriateness of discontinuing positive airway pressure (PAP) therapy. While 42-50% of trial participants achieved an AHI below 15 events per hour with minimal daytime sleepiness — thresholds at which PAP may not be recommended — any changes to your CPAP use should be made in close consultation with your sleep medicine provider and guided by follow-up sleep testing to confirm improvement.
Zepbound and Mounjaro both contain tirzepatide, a dual GIP/GLP-1 receptor agonist. However, they are approved for different conditions: Zepbound is FDA-approved for obesity and for moderate to severe OSA in adults with obesity, while Mounjaro is approved only for blood sugar control in type 2 diabetes. Ozempic (semaglutide) is a different medication — a GLP-1 receptor agonist (not a dual agonist) — approved for type 2 diabetes and cardiovascular risk reduction, but not for OSA treatment.
In the SURMOUNT-OSA clinical trials, tirzepatide reduced sleep apnea severity (measured by the apnea-hypopnea index, or AHI) by 50-59% from baseline over 52 weeks. The average AHI reduction was 20-24 events per hour compared to placebo. Approximately 42-50% of participants achieved mild or remission-level sleep apnea. Patients also experienced 17-20% body weight loss, reductions in blood pressure, and lower levels of inflammatory markers.
Capital ENT's board-certified otolaryngologists prescribe Zepbound directly in clinic for eligible patients with OSA and obesity — no referral to a separate weight-loss or endocrinology practice needed. We evaluate your sleep apnea severity, determine whether Zepbound is appropriate for you, and manage the medication alongside any other ENT or surgical care you may need. Comprehensive sleep apnea management often involves multiple approaches — including CPAP, surgical options, and weight-loss medications — tailored to each patient's anatomy and needs.
References
- Zepbound (tirzepatide) prescribing information. Food and Drug Administration. Updated February 24, 2026.
- FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
- Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity. N Engl J Med. 2024;391(13):1193-1205. doi:10.1056/NEJMoa2404881.
- Wu JY, Chen CC, Ling Tu W, et al. Clinical impact of tirzepatide on patients with OSA and obesity. Chest. 2025;S0012-3692(25)00436-2. doi:10.1016/j.chest.2025.03.030.
- Yang YT, Hou XZ, Zhang XR, Zhang ZP, Wang SH. Comparative effectiveness and safety of novel antidiabetic agents in the management of obstructive sleep apnea: a systematic review, meta-analysis, and network meta-analysis. Respir Med. 2026;253:108671. doi:10.1016/j.rmed.2026.108671.
- Moiz A, Filion KB, Tsoukas MA, et al. The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions. EClinicalMedicine. 2025;86:103363. doi:10.1016/j.eclinm.2025.103363.
- Malhotra A, Grunstein RR, Azarbarzin A, et al. Tirzepatide for sleep-disordered breathing in SURMOUNT-OSA: time course and association with body weight. Sleep Med. 2025;136:106853. doi:10.1016/j.sleep.2025.106853.
- Malhotra A, Grunstein R, Azarbarzin A, et al. Tirzepatide on obstructive sleep apnea-related cardiometabolic risk: secondary outcomes of the SURMOUNT-OSA randomized trial. Nat Med. 2026. doi:10.1038/s41591-025-04071-1.
- Nauck MA, Tuttle KR, Tschöp MH, Blüher M. Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits. Lancet. 2026;S0140-6736(25)02105-1. doi:10.1016/S0140-6736(25)02105-1.
- Tang H, Zhang B, Lu Y, et al. Incretin receptor agonists and CPAP use in adults with diabetes, obesity, and obstructive sleep apnea. JAMA Netw Open. 2025;8(12):e2550978. doi:10.1001/jamanetworkopen.2025.50978.
- Lastra AC, Neborak JM, Mokhlesi B. Diagnosis and treatment of obstructive sleep apnea. JAMA Intern Med. 2025;2837455. doi:10.1001/jamainternmed.2025.2318.
- Luu S, Chan DECY, Marshall NS, et al. Pharmacotherapy for obstructive sleep apnea: a critical review of randomized placebo-controlled trials. Sleep Med Rev. 2025;84:102169. doi:10.1016/j.smrv.2025.102169.
Interested in GLP-1 Treatment for Sleep Apnea?
Our board-certified otolaryngologists can evaluate your sleep apnea, discuss all available treatment options including Zepbound, and create a personalized care plan. Same-day and next-day consultations often available.